RCP
ABBV icon

Rothschild Capital Partners’s AbbVie ABBV Stock Holding History

Rothschild Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,590
Closed -$592K – 91
2025
Q4 		$592K Hold
2,590
– – 0.14% 44
2025
Q3 		$600K Hold
2,590
– – 0.14% 45
2025
Q2 		$481K Hold
2,590
– – 0.13% 43
2025
Q1 		$543K Buy
2,590
+440
+20% +$85.5K 0.14% 41
2024
Q4 		$382K Buy
+2,150
New +$395K 0.09% 58

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rothschild Capital Partners's ABBV Position: Q1 2026 in Review

Rothschild Capital Partners sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 2,590 shares — an estimated $592K sold.

Rothschild Capital Partners first reported a position in ABBV in Q4 2024 and held it in 5 quarters. The position peaked at $600K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Rothschild Capital Partners reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Rothschild Capital Partners sold 2,590 AbbVie shares in Q1 2026, an estimated $592K.
  • Rothschild Capital Partners first reported a position in AbbVie in Q4 2024 and held it in 5 quarters.
  • Rothschild Capital Partners's AbbVie position peaked at $600K in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Rothschild Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.